Influenza A (H5N1) pandemic prototype vaccine Fluval.
Identifieur interne : 000875 ( Ncbi/Merge ); précédent : 000874; suivant : 000876Influenza A (H5N1) pandemic prototype vaccine Fluval.
Auteurs : Zoltan Vajo [Hongrie]Source :
- Expert review of vaccines [ 1744-8395 ] ; 2009.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (pharmacologie), Composés de l'aluminium (pharmacologie), Flambées de maladies (), Grippe humaine (), Grippe humaine (épidémiologie), Hongrie, Humains, Phosphates (pharmacologie), Sous-type H5N1 du virus de la grippe A (génétique), Sous-type H5N1 du virus de la grippe A (immunologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (génétique), Vaccins antigrippaux (immunologie), Vaccins inactivés (effets indésirables), Vaccins inactivés (génétique), Vaccins inactivés (immunologie).
- MESH :
- effets indésirables : Vaccins antigrippaux, Vaccins inactivés.
- génétique : Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux, Vaccins inactivés.
- immunologie : Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux, Vaccins inactivés.
- pharmacologie : Adjuvants immunologiques, Composés de l'aluminium, Phosphates.
- épidémiologie : Grippe humaine.
- Flambées de maladies, Grippe humaine, Hongrie, Humains.
- Wicri :
- geographic : Hongrie.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (pharmacology), Aluminum Compounds (pharmacology), Disease Outbreaks (prevention & control), Humans, Hungary, Influenza A Virus, H5N1 Subtype (genetics), Influenza A Virus, H5N1 Subtype (immunology), Influenza Vaccines (adverse effects), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Phosphates (pharmacology), Vaccines, Inactivated (adverse effects), Vaccines, Inactivated (genetics), Vaccines, Inactivated (immunology).
- MESH :
- chemical , adverse effects : Influenza Vaccines, Vaccines, Inactivated.
- chemical , genetics : Influenza Vaccines, Vaccines, Inactivated.
- chemical , immunology : Influenza Vaccines, Vaccines, Inactivated.
- chemical , pharmacology : Adjuvants, Immunologic, Aluminum Compounds, Phosphates.
- geographic : Hungary.
- epidemiology : Influenza, Human.
- genetics : Influenza A Virus, H5N1 Subtype.
- immunology : Influenza A Virus, H5N1 Subtype.
- prevention & control : Disease Outbreaks, Influenza, Human.
- Humans.
Abstract
The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based.
DOI: 10.1586/erv.09.25
PubMed: 19397418
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001765
- to stream PubMed, to step Curation: 001765
- to stream PubMed, to step Checkpoint: 001578
Links to Exploration step
pubmed:19397418Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza A (H5N1) pandemic prototype vaccine Fluval.</title><author><name sortKey="Vajo, Zoltan" sort="Vajo, Zoltan" uniqKey="Vajo Z" first="Zoltan" last="Vajo">Zoltan Vajo</name><affiliation wicri:level="1"><nlm:affiliation>University of Debrecen, Medical and Health Science Center, Debrecen, Hungary. zoltanvajo@gmail.com</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>University of Debrecen, Medical and Health Science Center, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19397418</idno><idno type="pmid">19397418</idno><idno type="doi">10.1586/erv.09.25</idno><idno type="wicri:Area/PubMed/Corpus">001765</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001765</idno><idno type="wicri:Area/PubMed/Curation">001765</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001765</idno><idno type="wicri:Area/PubMed/Checkpoint">001578</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001578</idno><idno type="wicri:Area/Ncbi/Merge">000875</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza A (H5N1) pandemic prototype vaccine Fluval.</title><author><name sortKey="Vajo, Zoltan" sort="Vajo, Zoltan" uniqKey="Vajo Z" first="Zoltan" last="Vajo">Zoltan Vajo</name><affiliation wicri:level="1"><nlm:affiliation>University of Debrecen, Medical and Health Science Center, Debrecen, Hungary. zoltanvajo@gmail.com</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>University of Debrecen, Medical and Health Science Center, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author></analytic><series><title level="j">Expert review of vaccines</title><idno type="eISSN">1744-8395</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (pharmacology)</term><term>Aluminum Compounds (pharmacology)</term><term>Disease Outbreaks (prevention & control)</term><term>Humans</term><term>Hungary</term><term>Influenza A Virus, H5N1 Subtype (genetics)</term><term>Influenza A Virus, H5N1 Subtype (immunology)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (genetics)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Phosphates (pharmacology)</term><term>Vaccines, Inactivated (adverse effects)</term><term>Vaccines, Inactivated (genetics)</term><term>Vaccines, Inactivated (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (pharmacologie)</term><term>Composés de l'aluminium (pharmacologie)</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Hongrie</term><term>Humains</term><term>Phosphates (pharmacologie)</term><term>Sous-type H5N1 du virus de la grippe A (génétique)</term><term>Sous-type H5N1 du virus de la grippe A (immunologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (génétique)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins inactivés (effets indésirables)</term><term>Vaccins inactivés (génétique)</term><term>Vaccins inactivés (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Aluminum Compounds</term><term>Phosphates</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Hungary</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Composés de l'aluminium</term><term>Phosphates</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Flambées de maladies</term><term>Grippe humaine</term><term>Hongrie</term><term>Humains</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Hongrie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19397418</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert review of vaccines</Title><ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation></Journal><ArticleTitle>Influenza A (H5N1) pandemic prototype vaccine Fluval.</ArticleTitle><Pagination><MedlinePgn>619-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/erv.09.25</ELocationID><Abstract><AbstractText>The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vajo</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>University of Debrecen, Medical and Health Science Center, Debrecen, Hungary. zoltanvajo@gmail.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Vaccines</MedlineTA><NlmUniqueID>101155475</NlmUniqueID><ISSNLinking>1476-0584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017607">Aluminum Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010710">Phosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>F92V3S521O</RegistryNumber><NameOfSubstance UI="C012714">aluminum phosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017607" MajorTopicYN="N">Aluminum Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006814" MajorTopicYN="N" Type="Geographic">Hungary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010710" MajorTopicYN="N">Phosphates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>36</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19397418</ArticleId><ArticleId IdType="doi">10.1586/erv.09.25</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Hongrie</li></country></list><tree><country name="Hongrie"><noRegion><name sortKey="Vajo, Zoltan" sort="Vajo, Zoltan" uniqKey="Vajo Z" first="Zoltan" last="Vajo">Zoltan Vajo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000875 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000875 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:19397418
|texte= Influenza A (H5N1) pandemic prototype vaccine Fluval.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19397418" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |